Last updated on July 2019

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies


Brief description of study

The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

Clinical Study Identifier: NCT02807844

Find a site near you

Start Over